This article will introduce the GPCR targets and pipelines that received attention at the JP Morgan Healthcare Conference 2024.

Lirum BioMed Reveals Encouraging Results for Its Innovative Treatment LX-101, Showing Strong Early-Phase Effectiveness in Tackling IGF-Linked Tumors, Scheduled for Discussion at the 2024 ESMO Congress on Sarcoma and Uncommon Cancers.

Levetiracetam, a diminutive molecular entity, has been engineered to hone in on the synaptic vesicle protein 2A (SV2A) as a modulation target.

Nuvectis Pharma Releases Promising Initial Results from Early-Stage NXP800 Study in Platinum-Resilient Ovarian Cancer with ARID1a Alterations.

On March 11th, Boehringer Ingelheim partnered with Sosei Group in an exclusive deal to create and market a novel schizophrenia drug, a GPR52 agonist.

Individuals who should not take semaglutide are:Those with multiple endocrine neoplasia type 2 (MEN2),medullary thyroid cancer,diabetic ketoacidosis (DKA)

Ketoconazole, a diminutive molecular compound, functions as an inhibitor of CYP51A1.

Mozart Therapeutics Showcases Preliminary Data for Key Project, MTX-101, Aimed at Autoimmune Condition Management, at the 2024 Society of Toxicology Gathering.

On February 28th, US-based Viatris and Swiss firm Idorsia launched a major R&D partnership, with Viatris securing exclusive global rights for two Phase 3 drugs, Selatogrel and Cenerimod, and options for future joint projects.

Madrigal Pharmaceuticals Reveals Rezdiffra™ (resmetirom) Gets Green Light from FDA to Manage Noncirrhotic NASH Sufferers with Moderate to Severe Fibrotic Liver Conditions.

Misoprostol is a small molecule drug that exerts its pharmacological effects through the activation of EP2 receptors in the body.

Zai Lab Limited plans to present early data highlighting the potential therapeutic effects of its global antibody-drug conjugate project, ZL-1310.